Royal Bank of Canada Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold

Royal Bank of Canada downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) from a moderate buy rating to a hold rating in a research note issued to investors on Friday morning, Marketbeat reports. The brokerage currently has $662.00 target price on the biopharmaceutical company's stock.

A number of other research analysts have also commented on the company. UBS Group cut their target price on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Bernstein Bank cut their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $874.56.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $112.15 during trading hours on Friday, reaching $493.24. 6,307,887 shares of the company's stock were exchanged, compared to its average volume of 829,463. Regeneron Pharmaceuticals has a fifty-two week low of $485.00 and a fifty-two week high of $1,211.20. The stock has a market capitalization of $53.25 billion, a P/E ratio of 12.89, a P/E/G ratio of 2.34 and a beta of 0.43. The business has a fifty day moving average price of $584.25 and a 200-day moving average price of $665.66. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the firm earned $9.55 earnings per share. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.71%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pamalican Asset Management Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $4,915,000. Intact Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $356,000. Rhenman & Partners Asset Management AB lifted its holdings in shares of Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after purchasing an additional 4,457 shares in the last quarter. Fagan Associates Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after purchasing an additional 3,832 shares in the last quarter. Finally, Golden State Equity Partners lifted its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after purchasing an additional 1,272 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.